Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.67 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.63 |
| ▸ | POLA1 | P09884 | 1/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8843889 | 0.90 | GDA (0.69) | XDHGDAPOLA1 | |
| SCHEMBL27569987 | 0.87 | GDA (0.59) | XDHGDAPOLA1 | |
| SCHEMBL27550540 | 0.87 | GDA (0.59) | XDHGDAPOLA1 | |
| SCHEMBL1965519 | 0.84 | GDA (0.71) | XDHGDAPOLA1 | |
| SCHEMBL5352879 | 0.82 | SPHK2 (0.52) | XDHGDASPHK2SPHK1NPC1 | |
| SCHEMBL8535457 | 0.80 | XDH (1.00) | XDHGDAPOLA1 | |
| SCHEMBL4384744 | 0.80 | XDH (1.00) | XDHGDAPOLA1 | |
| Acetic Acid SCHEMBL27671662 | 0.80 | XDH (0.88) | XDHGDAPOLA1 | |
| Hydrochloric Acid SCHEMBL258899 | 0.79 | XDH (0.97) | XDHGDAPOLA1 | |
| SCHEMBL3072990 | 0.79 | GDA (0.67) | XDHGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307166-B1 | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | PRO-NEURON, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1157698-A2 | Treatment of inflammatory diseases with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6060459-A | Enhancing blood cell count with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| US-6054441-A | Antiinflammatory agents; treatment of bacterial, viral or fungal infections; autoimmune diseases | PRO-NEURON, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0771204-A4 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO NEURON INC (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0771204-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996004923-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| US-4880782-A | 3'-AZIDO-2',3'-DIDEOXYINOSINE AND RELATED COMPOUNDS FOR AIDS | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1989-11-14 | — | — | US | disclosed |
| EP-0332626-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS IN HUMANS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1989-09-20 | — | — | EP | disclosed |
| EP-0286825-A2 | Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1988-10-19 | — | — | EP | disclosed |
| US-4145531-A | Process for producing 2'-substituted-D-ribofuranosyl purine compounds | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | TPMT, NUDT1, ENTPD5 | XDH 98/4885GDA 74/4885POLA1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.